No claim is made by the authors that the scale could not be improved, nor that it could not be com pleted during more regular intervals during the 24 hours, giving a more complete record of a patient's behaviour. Clearly it could be so used, and this would answer one of the points in the letter criticising the trial's design (Journal, November 1987, 151, 705â€" 706) . Any scale, no matter how unsophisticated it may appear and even be, is better than none and I, for one, am grateful for the efforts undertaken by Dr Craft and his colleagues in proving the validity of it despite its imperfections. Included in my gratitude are the unnamed nurse assessors who administered the scale during both its verification and use. In the absence of a disclaimer it has to be assumed that anticholinergic drugs were prescribed to at least some of the patients. Callaway (1984) described an increase of P3-latency after scopola mine, and in our patient group P3-latency was correlated significantly with dose of anticholinergic medication (Kendall's t = 0.48, P< 0.01). We agree with Romani et al that neuroleptic medication is unlikely to account for P3 changes. Blackwood et a! (1987) found no intra-subject differences before and after initiation of neuroleptic drug therapy, and for our patients there was no correlation between dose of neuroleptic (in chlorpromazine units) and P3-latency or amplitude. Pfefferbaum et al (1984) did not report an absence of a neuroleptic drug effect on ERPs as suggested by Romani et al.
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